ArticleBMC cancer2025
Suicide risk transition and cumulative incidence post-cancer diagnosis: retrospective cohort study utilizing population-based cancer registry in Japan.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Suicide Risk and Associated Factors in Patients with Pancreatic Cancer: A Systematic Review.Diseases (Basel, Switzerland) · 2026Review
- Suicide Risk in Glioblastoma Multiforme: A Brief Review of Risk Factors, Screening, and Prevention.Current psychiatry reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSuicide risk in cancer patients peaks early post-diagnosis; however, detailed studies on its changes are scarce. We analyzed population-based cancer registry data to identify trends in suicide risk and incidence following diagnosis among cancer patients.
methodsData of cancer patients who died between 2016 and 2018 were used for descriptive analysis, while data of patients who were newly diagnosed during the same period were used to calculate standardized mortality ratios (SMRs) and conduct survival and multivariable analyses. The diagnostic data included follow-up information through the end of 2019. All data were obtained from the Kanagawa Cancer Registry. The SMRs for suicide were calculated every 3 months up to 48 months post-diagnosis. Cumulative incidences of suicide were calculated using survival analysis. Risk factors associated with suicide were identified with multivariable analysis using the Fine and Gray method.
resultsAmong the 105 598 cancer patients who died during the study period, 282 patients (0.27%) died by suicide. The SMRs of suicides were 2.71 (95% confidence interval [CI]: 1.99-3.60) and 2.10 (95% CI: 1.64-2.66) up to 6 months and 1 year post-diagnosis, respectively. The maximum change in the 3-month interval SMR was 3.45 (95% CI: 2.34-4.89) within the first 3 months, subsequently decreasing to the same level as that of the general population and temporarily increasing again in 13-15 months. In the survival analysis, the cumulative suicide rates at 6 and 12 months were 0.23% and 0.33%, respectively. In the multivariate analysis, suicide risk was significantly higher in patients with intermediate or poor prognosis cancer sites and lower in females.
conclusionsSuicide among cancer patients is a rare event in the aggregate, but it still occurs in small numbers and should be addressed. The bimodal increase in SMR suggests the influence of adverse outcomes, such as cancer diagnosis, recurrence, and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.